Vaccine efficacy and production performance of pigs vaccinated with RespiSure-ONE~(TM)

摘要

Mycoplasma hyopneumoniae is the primary pathogen of enzootic pneumonia in pigs. Clinical signs of myco-plasmal infection include a dry, nonproductive cough and a depressed appetite, which results in reduced average daily gain and feed efficiency. Although marginally pathogenic on its own, M. hyopneumoniae interacts with other respiratory pathogens to increase the severity of porcine respiratory disease complex (PRDC). Up to 93% of swine herds worldwide are infected with myco-plasmal pneumonia, making it one of the most prevalent and costly swine diseases. The annual cost to pork producers has been estimated to be over 1 billion dollar. Previous studies have shown RespiSure-ONE to be effective in preventing mycoplasmal pneumonia 23 weeks after vaccination. Two studies were conducted in Europe to corroborate these U.S. studies. A clinical study conducted in Hungary evaluated the ability of RespiSure-ONE (marketed as Stellamune-ONCE in Europe) to prevent pneumonia and improve weight gains when pigswere challenged 18 or 23 weeks after vaccination. A field study conducted in Germany evaluated the efficacy of RespiSure-ONE in preventing clinical pneumonia and providing economic value to commercial pork producers.